Wiktoria Gocal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wiktoria Gocal has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Lorela Ciraku
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania
14 shared publications - Mauricio J. Reginato
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine
14 shared publications - Nicole L. Simone
Department of Radiation Oncology, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
14 shared publications - Alexandra N. Talarico
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania
13 shared publications - Alexej Dick
Department of Biochemistry & Molecular Biology Drexel University College of Medicine Philadelphia Pennsylvania USA
13 shared publications - Emily M. Esquea
Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania
13 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2 inhibitor induces cell death and lipid peroxidation in BCBM cells and is blocked by ferrostatin treatment.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2 inhibitor induces cell death and lipid peroxidation in BCBM cells and is blocked by ferrostatin treatment.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2-S267D mutant increases growth in the brain but not mammary fad pad and can partly rescue effects of CDK5 knockdown in BCBM cells.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2-S267D mutant increases growth in the brain but not mammary fad pad and can partly rescue effects of CDK5 knockdown in BCBM cells.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Genetic targeting of ACSS2 induces cell death and lipid peroxidation in BCBM cells and is blocked by ferrostatin treatment.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Genetic targeting of ACSS2 induces cell death and lipid peroxidation in BCBM cells and is blocked by ferrostatin treatment.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
RNA-seq data of RNAi ACSS2 in BCBM cells.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
RNA-seq data of RNAi ACSS2 in BCBM cells.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
E2F1 overexpression can protect from erastin and ACSS2 inhibitor mediated ferroptosis and E2F1 levels are elevated in BCBM cells compared to parentals.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
E2F1 overexpression can protect from erastin and ACSS2 inhibitor mediated ferroptosis and E2F1 levels are elevated in BCBM cells compared to parentals.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Quantification of western blots from Figure 1B.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Quantification of western blots from Figure 1B.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
E2F1 binds SLC7A11 promoter and OGT-CDK5-ACSS2 pathway regulates E2F1 and SLC7A11 levels in breast cancer cells.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
E2F1 binds SLC7A11 promoter and OGT-CDK5-ACSS2 pathway regulates E2F1 and SLC7A11 levels in breast cancer cells.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2 inhibitor shrinks preformed tumor and is blocked by ferrostatin treatment in BCBM cells ex vivo.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
ACSS2 inhibitor shrinks preformed tumor and is blocked by ferrostatin treatment in BCBM cells ex vivo.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Overexpression of OGT or CDK5 can increase breast cancer growth in the brain and ACSS2 is required for tumor growth in the brain but not in the mammary fat pad.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Overexpression of OGT or CDK5 can increase breast cancer growth in the brain and ACSS2 is required for tumor growth in the brain but not in the mammary fat pad.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Novel ASCC2 inhibitor AD-5584 shrinks preformed tumors ex vivo, in vivo and in BCBM-PDxO model in vitro.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis
Novel ASCC2 inhibitor AD-5584 shrinks preformed tumors ex vivo, in vivo and in BCBM-PDxO model in vitro.